KEM® identified the most responsive subgroup to the proinsuline-derived therapy. And CD4/GRB+(CD4, granzyme B+ T-cell) was associated with the dose and identified as a surrogate endpoint

Ariana and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer.

Ariana shows that patients receiving the VAL401 treatment have statistically significant improvement in Overall Survival compared to those receiving no treatment, as well as a measurable improvement on Quality of Life.

Ariana successfully created a Synthetic Control Arm (SCA) to evaluate the efficacy of a treatment against Alzheimer.

Ariana and collaborators across Brazil, Mexico, and Colombia conducted a large retrospective cohort study involving over 125 million health records to assess the impact of dengue on healthcare systems.

Ariana utilized KEM® xAI to analyze 126 million hospital records from the SAEH and SIHSUS databases in Mexico and Brazil, focusing on influenza admissions.

Ariana, in collaboration with ANAVEX Life Sciences Corp, advanced the clinical development of ANAVEX®2-73, a Sigma-1 receptor agonist targeting Alzheimer's disease, leveraging Next Generation Sequencing for biomarker identification.

Ariana, under the guidance of Professor Jean-Charles Soria and in collaboration with multiple international institutes, conducted the WINTHER clinical trial, a trailblazing initiative in personalized cancer treatment using transcriptomics.

At the Alzheimer's Association International Conference 2019, Ariana Pharma, alongside several leading academic institutions, presented pioneering research on early Alzheimer's detection through the integration of omics and imaging data.

In a collaborative study between Ariana Pharmaceuticals and Harvard Medical School’s Massachusetts General Hospital Cancer Center, researchers focused on identifying biomarkers for synergistic drug combinations in melanoma treatment.

Patient derived xenograft mouse models (PDX) experiments combined with AI provide an opportunity to simulate a preclinical assessment using multiple mice. The platform was tested on colon cancer patients derived PDX.

Taking advantage of transcriptomic data generated in a cohort of 81 NSCLC patients, KEM® identifies molecular biomarkers linked with NSCLC disease progression to predict survival in patients treated with immunotherapy.